XNAS · Healthcare · Biotechnology
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.33 | -0.35 | -6.06% | $0 | ❌ Miss | +0.00% | +1.76% | — |
| 2026-02-26 | Q4 2025 | -0.36 | -0.36 | +0.00% | $0 | ❌ Miss | +0.39% | -7.80% | -29.08% |
| 2025-11-06 |
| Q3 2025 |
| -0.36 |
| -0.37 |
| -2.78% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.33 | -0.36 | -9.09% | $0 | ❌ Miss | -2.02% | +17.47% | +35.38% |
| 2025-02-27 | Q4 2024 | -0.17 | -0.22 | -29.41% | $0 | ❌ Miss | +4.08% | +3.11% | -24.15% |
| 2024-11-13 | Q3 2024 | -0.20 | -0.20 | +0.00% | $0 | ➖ Inline | +3.63% | -10.06% | -14.08% |
| 2024-03-08 | Q4 2023 | -0.21 | -0.16 | +23.81% | $0 | ✅ Beat | — | — | — |
| 2023-11-14 | Q3 2023 | -0.29 | -0.21 | +27.59% | $0 | ✅ Beat | -9.83% | -4.22% | +9.33% |
Showing last 8 quarters.